Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Explore private companies / Insilico Medicine IPO
Insilico Medicine

Insilico Medicine IPO

$1B
Last Known Valuation, Jan 2026
Register for details
For more details on financing and valuation of private companies similar to Insilico Medicine before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Insilico Medicine IPO date and status

2014
Founded
Dec 2025
IPO Completed

Company details

Insilico Medicine is a biotech company that utilizes generative AI with the goal of accelerating drug discovery and development. Its proprietary Pharma.AI platform aims to integrate biology, chemistry, and clinical development to efficiently advance novel drug candidates through its fully self-generated AIDD pipeline. Core values of patient focus, relentless innovation, and transparency guide Insilico Medicine's mission to revolutionize healthcare with advanced biotechnological solutions. Insilico Medicine was founded by Alex Zhavoronkov in 2014 and is headquartered in Hong Kong.
Founded
2014
Headquarters
Pak Shek Kok, Hong Kong S.A.R.
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
No longer available
Total Funding
No longer available
Last Funding Round
No longer available

Learn more about Insilico Medicine

To invest in Insilico Medicine pre-IPO

Can you invest in Insilico Medicine pre-IPO?

You may invest in Insilico Medicine as it is a public company listed on the HKEX with ticker 3696.HK. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Insilico Medicine before it goes public?

You can no longer sell shares of Insilico Medicine on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Insilico Medicine shares?

Forge can no longer determine the value of Insilico Medicine shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Insilico Medicine a publicly traded company?

Insilico Medicine became a public company following its IPO on 12/30/2025 and is now traded on the HKEX under the ticker 3696.HK.

To learn more about Insilico Medicine potential IPO

Will Insilico Medicine go IPO?

Insilico Medicine became a public company following its IPO on 12/30/2025 and is now traded on the HKEX under the ticker 3696.HK.

What is Insilico Medicine’s IPO price?

The IPO price of Insilico Medicine is not currently available.

When was Insilico Medicine founded?

Insilico Medicine was founded in 2014.

What is Insilico Medicine funding to date?

The funding to date for Insilico Medicine is not currently available.

Insilico Medicine major investors

A-Level Capital
Baidu Ventures
Bold Capital Partners
Deerfield Management
Eight Roads Ventures
Lilly Asia Ventures
Longevity Vision Fund
Mirae Asset Capital
Orbimed
Pavilion Capital Group
Qiming Venture Partners
Sinovation Ventures
Warburg Pincus
Wuxi Apptec

Insilico Medicine pre-IPO valuation and funding rounds

Last known valuation details
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
Funding Round Details are not yet available for this company.

Insilico Medicine IPO news and media highlights

Chinese Investors Lead US-Based Insilico Medicine's USD100 Million-Plus Series E Round

Shanghai's Pudong Venture Capital and Hong Kong's Value Partners Group will jointly lead American biotechnology startup Insilico Medicine's Series E funding round, which is expected to exceed USD100 million.

Insilico Medicine reports preliminary data from Phase IIa IPF treatment trial

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug designed using generative AI, to treat idiopathic pulmonary fibrosis (IPF). The randomised, double-blind, placebo-controlled trial was conducted across 21 sites in China, enrolling 71 patients with IPF. It assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12-week oral ISM001-055.

Hong Kong-based biotech Insilico Medicine shifts IPO plan to city from New York

Hong Kong-based biotech company Insilico Medicine has set its sights on an initial public offering in the city, shelving its earlier New York fundraising plan, as the start-up seeks capital to finance clinical trials of drugs discovered and designed by artificial intelligence. While details such as the IPO timetable or the amount have not been disclosed, the company in an exchange filing on Tuesday named Morgan Stanley, China International Capital Corporation and BNP Paribas Securities Asia as its overall coordinators.

The first fully A.I.-generated drug enters clinical trials in human patients

The first drug fully generated by artificial intelligence entered clinical trials with human patients this week. Insilico Medicine, a Hong Kong-based biotech startup with more than $400 million in funding, created the drug, INS018_055, as a treatment for idiopathic pulmonary fibrosis, a chronic disease that causes scarring in the lungs. The condition, which has increased in prevalence in recent decades, currently affects about 100,000 people in the U.S. and can lead to death within two to five years if untreated, according to the National Institutes of Health.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Healthcare Software
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Spyglass PharmaSpyglass PharmaNot available$ xx.xxSeries D$350.04MM$2.33$75MM
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
OriginOriginNot available$ xx.xxNot available------

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $550.00 +$102.77 (22.98%)High $xxx.xx
Anduril Anduril $114.78 +$9.78 (9.31%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $114.78 +$9.78 (9.31%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx
Groq Groq $29.77 -$0.01 (0.03%)High $xxx.xx

Forge, your trusted partner for pre-IPO insights and Insilico Medicine data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Jan 3, 2026

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.